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TO THE EDITOR—We appreciate the
thoughtful comments raised by Wolbers
and Day [1] in response to our article [2].
We agree with their primary point—that
ourmeta-analysis summarized data across
studies, and it is therefore best suited to
evaluate study-level and not individual-
level predictors of outcomes. We should
have speciﬁed more clearly that our anal-
ysis is best suited for drawing inferences
about relationships among patient popu-
lations, but not about individual patients.
Indeed, this point is true for almost all
meta-analysis, and it also applies to most
individual randomized trials [3].
It is important to note that we did not
intend to imply that combination am-
photericin B and ﬂucytosine conferred
a beneﬁt in patients with cryptococcal
meningitis with altered mental status.
Rather, in our meta-analysis, we were un-
able to identify a statistically signiﬁcant
treatment beneﬁt across all published lit-
erature, for combination amphotericin B
with ﬂucytosine over amphotericin B alone.
Although there was some implication of a
beneﬁt from adjunctive ﬂucytosine in a
subanalysis limited to studies that included
patients with altered levels of conscious-
ness, this estimate was not statistically sig-
niﬁcant (odds ratio = 0.56; 95% conﬁdence
interval [CI], .23–1.43) (Figure 1). As such,
we hypothesized in the discussion that
populations with altered consciousness
might be more likely to beneﬁt from
adjunctive ﬂucytosine therapy. If this
hypothesis were correct, it would require
patient-level data for conﬁrmation.
In their recent large, randomized trial,
Day et al [4] demonstrated superiority of
combination amphotericin B and ﬂucy-
tosine over amphotericin B alone at 10
weeks. They now present a subanalysis
with patient-level data that suggests that
those with a normal Glasgow Coma
Score (GCS) appeared to derive as much
beneﬁt (if not more) from the addition of
ﬂucytosine as those with a GCS < 15. Al-
though their study was not powered to
detect differences in these subgroups,
their data do lend support to the use of
ﬂucytosine in individual patients with
normal mental status within their study
population. It should be noted that the
overall mortality in their study was 36%
at 10 weeks (and 30% among those who
received amphotericin B and ﬂucytosine
combination therapy). In contrast, the
only other large randomized trial to com-
pare amphotericin B alone with ampho-
tericin B and adjunctive ﬂucytosine found
no difference in mortality between groups
at 10 weeks (6.7% versus 6.9%; relative
risk = 0.97; 95% CI, .46–2.04) [5]. It is
noteworthy that this other study was con-
ducted in the United States, excluded
comatose patients from enrollment, and
had a lower prevalence of participants
with altered mental status than the Day
et al [4] study (11% vs 28%).
We believe that the contrasting data
from these 2 studies are in line with our
overall conclusion: that current available
evidence suggests that the adjunctive use
of ﬂucytosine might be beneﬁcial in popu-
lations with advanced disease who are at
high overall risk for mortality. As Wolbers
and Day [4] point out, this does not neces-
sarily mean that patients with normal
mental status will not beneﬁt from adjunc-
tive ﬂucytosine, only that populations with
low overall risk ofmortality are less likely to
Figure 1. Forrest plot from network meta-analysis comparing odds of early (2-week) and late (10-week) mortality between combination amphotericin B
and ﬂucytosine with amphotericin B alone for human immunodeﬁciency virus-associated cryptococcal meningitis. Abbreviations: AmB, amphotericin B; 5FC,
ﬂucytosine; CI, conﬁdence interval.
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beneﬁt. Unfortunately, for the time being,
it appears that ﬂucytosine is largely only
available and in use in the areas of the
world where the current data suggest it has
the least beneﬁt, whereas populations with
the highest mortality often cannot access it
[6, 7]. Indeed, the most important conclu-
sion we draw from our study is that more
data is required, across a range of patient
populations and disease stages, to elucidate
which drugs are needed for which patients,
and to ensure that the optimal therapies
are available to those who need them.
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